VRTX Stock Recent News
VRTX LATEST HEADLINES
Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and Alyftrek launch progress.
Are you reluctant to invest in stocks right now? That's understandable.
Many investors view the healthcare sector as a safe haven when the stock market is turbulent. That's understandable.
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $502.92, signifying a +1.51% move from its prior day's close.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Gilead Sciences (GILD) or Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the better value opportunity right now?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?
The Investment Committee give you their top stocks to watch for the second half.
As of March 11, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
When you're on an airplane, the pilot or a flight attendant will typically announce over the loudspeaker to "buckle your seatbelt" when the air is turbulent. That could be good advice for investors right now, too.
The past decade has been a game-changing one for Vertex Pharmaceuticals (VRTX 2.40%). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since gained the regulatory nod for four more and become the global leader in the CF market.